Medicare GLP-1 Bridge vs Compounded GLP-1: Which Is Cheaper?

The honest answer is that it depends entirely on whether you qualify for the Bridge. If you do, $50 a month is hard to beat, and it will almost always undercut compounded GLP-1 pricing. The catch is that most people won’t qualify, because the Bridge requires Medicare drug coverage plus a specific set of clinical criteria, and it excludes anyone already getting a GLP-1 through Part D. For everyone outside that narrow window, which is the large majority of people asking this question, compounded GLP-1 through a cash-pay telehealth program is the cheaper and more widely available route. Here’s how the two stack up so you can tell which group you’re in.

The two options side by side

The Bridge is a temporary Medicare demonstration that runs from July 1, 2026 through December 31, 2027. Compounded GLP-1 through telehealth is a year-round cash-pay option with no insurance involved. They aren’t really competing for the same person, which is the whole point of comparing them.

Who the Bridge is cheaper for

If you clear the eligibility bar, the Bridge wins on price, plainly. Fifty dollars is below the floor of compounded cash pricing, and far below brand-name cash pricing through NovoCare or LillyDirect.

To qualify, you need to be enrolled in a standalone Part D plan or a Medicare Advantage plan with drug coverage, and you need to meet one of these: a BMI of 35 or higher, or a BMI of 30 or higher with heart failure, uncontrolled hypertension, or chronic kidney disease, or a BMI of 27 or higher with prediabetes, a prior heart attack, a prior stroke, or symptomatic peripheral artery disease. You also can’t already be receiving a GLP-1 through Part D for another reason like diabetes or sleep apnea. If all of that describes you, take the $50.

Who compounded is cheaper for

Here’s where most readers land. If you’re under 65 and not on Medicare, the Bridge isn’t available to you at all, so the comparison is moot and compounded cash pricing is your floor. If you’re on Medicare but your BMI and conditions don’t hit the thresholds, you’re out. If you already get a GLP-1 through Part D for diabetes, you stay on that and can’t use the Bridge for weight loss. And if you want a formulation the Bridge doesn’t cover, such as Zepbound vials rather than the KwikPen, the program won’t pay for it.

For all of those people, compounded semaglutide or tirzepatide through a cash-pay program generally runs a few hundred dollars a month, with no prior authorization and no eligibility paperwork tied to BMI at the start of treatment. It’s available whether or not you have insurance, and it doesn’t expire at the end of 2027.

The asterisks that change the math

Even when the Bridge is cheaper on paper, three details are worth weighing. The $50 you pay each month does not count toward your Part D deductible or your annual out-of-pocket cap, because the Bridge sits outside the normal benefit. Low-income subsidy help, often called Extra Help, does not apply to Bridge medications. And you can’t stack a manufacturer coupon to push the cost below $50.

None of those make $50 a bad deal against a four-figure list price. But they matter if you were expecting Bridge spending to move you toward catastrophic coverage faster, because it won’t.

Two quick scenarios

Consider a scenario where a 68-year-old on a Part D plan has a BMI of 36 and wants Wegovy for weight loss, with no diabetes diagnosis. They qualify cleanly, and $50 a month beats every other route. The Bridge is the answer.

Now consider a scenario where a 54-year-old with employer insurance and a BMI of 31 wants to start a GLP-1. They aren’t on Medicare, so the Bridge doesn’t exist for them. Their realistic choices are whatever their commercial plan covers (often with prior authorization and step therapy) or compounded cash-pay at a few hundred dollars a month. Same drug class, completely different decision, and the Bridge never enters the picture.

Why the underlying medication is what matters

Whichever path is cheaper for you, the clinical value comes from the molecule, and tirzepatide in particular has strong data in exactly the older, metabolically complex group the Bridge targets. In the SURPASS-5 trial, adults with type 2 diabetes who added tirzepatide to insulin glargine lost about 10.9 kg on the highest dose over 40 weeks, while the placebo group gained about 1.6 kg, and more than 85% of tirzepatide patients reached an A1c under 7%. Results like that hold whether the tirzepatide reaches you through a $50 Bridge copay or a compounded vial, which is why the cost route is worth getting right.

If the Bridge isn’t a fit

If you’ve worked through the criteria and the Bridge isn’t available to you, a cash-pay telehealth program is the straightforward alternative. TrimRx connects you with licensed providers who prescribe semaglutide or tirzepatide when it’s clinically appropriate, and it bundles the provider visit and shipping into a flat monthly structure with no insurance required, across a program range of $179 to $1,579 depending on the medication and plan. There’s no BMI-at-initiation attestation and no prior authorization to clear.

To see which route is cheapest for your specific situation, the free assessment quiz takes a few minutes.

This article is for general information and is not medical or insurance advice. Eligibility, covered formulations, and pricing for the Medicare GLP-1 Bridge are set by CMS and participating manufacturers and can change. Confirm current details with Medicare and your prescriber before deciding.